George Poulogiannis

George Poulogiannis

Company: The Institute of Cancer Research

Job title: Team Leader, Signaling & Cancer Metabolism


Harnessing the Metabolism of PI3K Signaling for More Effective Anti-Cancer Therapy 10:45 am

• Metabolic fingerprinting can assist with the diagnosis and therapy decision-making of PIK3CA mutant cancers • PI3K/AKT activation drives the overproduction of bio-active lipids to support cell proliferation and migration beyond a cell-autonomous manner • Diet boosts the effectiveness of targeted therapies in PIK3CA-induced tumorigenesisRead more

day: Day Two

Panel Discussion: Making PI3K Inhibitors Work in the Clinic 3:00 pm

• Developing effective combination strategies • Targeting beyond the PI3K pathway • Disease specific resistance mechanisms • Isoform specific vs Pan PI3K inhibitors in mitigating resistanceRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.